Gleason 5级模式与雄激素剥夺治疗联合放疗后转移风险增加相关:RTOG 9202和9902分析
该研究汇总RTOG 9202(n=1292)和RTOG 9902(n=378)接受雄激素剥夺治疗联合放疗的前列腺癌患者,评估Gleason评分及Gleason 5级模式(GP5)与生化失败、局部失败、远处转移和总生存的关系。中位随访9.4年,GS 8-10且含GP5者远处转移劣于GS 4+4,10年DM分别高11%和18%;多因素分析限长期ADT者GP5显著增加DM(HR=0.43,95%CI 0.24-0.76,p=0.0039)。
要点
- 含GP5的GS 8-10患者远处转移风险显著高于GS 4+4,10年DM高11%和18%。
- 长期ADT亚组多因素分析GP5显著增加DM(HR=0.43,95%CI 0.24-0.76,p=0.0039)。
- GP5与生化失败和局部失败无显著关联,OS仅呈劣化趋势。
核心结论
- GP5是独立预后因素,对远处转移的预测最强,应在GS 8患者分层时考虑GP5。
研究设计与样本
- 汇总RTOG 9202(n=1292)和RTOG 9902(n=378)接受ADT联合放疗的患者,分析GS和GP5与BF、LF、DM、OS的关联。
- 采用Fine and Gray回归和累积发生率方法进行单因素和多因素分析,中位随访9.4年。
主要发现
- GS 8-10含GP5者DM劣于GS 4+4,RTOG 9202 p=0.038,RTOG 9902 p<0.001。
- 10年DM含GP5者较GS 4+4分别高11%(RTOG 9202)和18%(RTOG 9902)。
- OS呈劣化趋势:RTOG 9202 p=0.059,RTOG 9902 p=0.089,BF和LF无差异。
- 长期ADT亚组多因素分析GP5显著增加DM(HR=0.43,95%CI 0.24-0.76,p=0.0039),OS趋势(HR=0.74,95%CI 0.54-1.0,p=0.052),LF(HR=0.55,95%CI 0.28-1.09,p=0.085)和BF(HR=1.15,95%CI 0.84-1.59,p=0.39)无显著关联。
- Gleason 3+5、5+3与Gleason 9-10之间未观察到实质差异。
关键数值与推荐
- GS 8-10含GP5者10年DM较GS 4+4高11%(RTOG 9202)和18%(RTOG 9902)。
- 长期ADT亚组GP5增加DM的HR=0.43(95%CI 0.24-0.76,p=0.0039)。
临床怎么用
- 对GS 8患者进行分层时应考虑GP5状态以识别远处转移高风险人群。
- 含GP5的GS 8患者可能是评估新获批全身治疗或额外局部治疗的候选人群。
局限性
- 原文未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/PURPOSE: Stratification of Gleason score (GS) into three categories (2-6, 7, and 8-10) may not fully utilize its prognostic discrimination, with Gleason pattern 5 (GP5) previously identified as an independent adverse factor. MATERIALS/METHODS: Patients treated on RTOG 9202 (n = 1292) or RTOG 9902 (n = 378) were pooled and assessed for association of GS and GP5 on biochemical failure (BF), local failure (LF), distant metastasis (DM), and overall survival (OS). Fine and Gray's regression and cumulative incidence methods were used for univariate and multivariate analyses. RESULTS: With median follow-up of 9.4 years, patients with GS 8-10 with GP5 had worse outcome than GS 4 + 4 for DM on both RTOG9202 (p = 0.038) and RTOG9902 (p < 0.001) with a trend toward worse OS (p = 0.059 and p = 0.089, respectively), but without differences in BF or LF. At 10-years DM was higher by 11% (RTOG 9202) and 18% (RTOG 9902) with GP5 compared to GS 4 + 4. On multivariate analysis restricted to long-term androgen deprivation therapy the presence of GP5 substantially increased distant metastasis (HR = 0.43, 95%CI: 0.24-0.76, p = 0.0039) with a trend toward worse OS (HR:0.74, 95% CI:0.54-1.0, p = 0.052) without association with LF (HR:0.55, 95%CI:0.28-1.09, p = 0.085) or BF (HR:1.15, 95%CI:0.84-1.59, p = 0.39). We did not observed substantial differences between Gleason 3 + 5, 5 + 3, or Gleason 9-10. CONCLUSIONS: These results validate GP5 as an independent prognostic factor which is strongest for DM. As a result GP5 should be considered when stratifying patients with GS 8 and may be a patient population in which to evaluate newly approved systemic therapies or additional local treatments.
引用
- Hamstra DA, Pugh SL, Lepor H, et al. Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation: An analysis of RTOG 9202 and 9902. Radiother Oncol. 2019. PMID: 31540746. doi:10.1016/j.radonc.2019.08.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。